Mohamed M A Zaitoun1, Mohammad Abd Alkhalik Basha2, Farouk Hassan3, Saeed Bakry Elsayed1, Alaa A Farag4, Mahmoud Amer4, Sameh Abdelaziz Aly5, Nahla Zaitoun6. 1. Department of Radiodiagnosis, Zagazig University, Zagazig 644631, Egypt. 2. Department of Radiodiagnosis, Zagazig University, Zagazig 644631, Egypt. Electronic address: Mohammad_basha76@yahoo.com. 3. Department of Radiodiagnosis, Cairo University, Cairo, Egypt. 4. Department of Internal Medicine, Zagazig University, Zagazig 644631, Egypt. 5. Department of Radiodiagnosis, Benha University, Benha, Egypt. 6. Department of Community and Family Medicine, Zagazig University, Zagazig 644631, Egypt.
Abstract
PURPOSE: To evaluate the effect of left gastric artery embolization (LGAE) on glycated hemoglobin (HbA1c) in a prospective obese, prediabetic cohort. MATERIALS AND METHODS: This prospective pilot study included 10 obese, prediabetic patients (7 females and 3 males; mean age 37.5 ± 8.8 years; range 28-51 years) admitted to the Interventional Radiology Unit between January 2017 and June 2018 for LGAE for weight reduction. The main inclusion criteria were body mass index (BMI) >30 kg/m2 and HbA1c ranging from 5.7 to 6.4. Body weight, BMI, and HbA1c were assessed for each patient preprocedure and at 6 months postprocedure. Statistical analysis was performed using a paired sample t test. RESULTS: The baseline mean body weight, BMI, and HbA1c were 107.4 ± 12.8 kg, 37.4 ± 3.3 kg/m2, and 6 ± 0.2, respectively. Concerning complications, no serious adverse events were detected. Six months after the procedure, the mean body weight and BMI significantly decreased to 98 ± 11.6 kg and 34.1 ± 3 kg/m2, respectively (P < .0001). A paired sample t test showed a significant reduction in HbA1c from pre- to postprocedure (6.1 ± 0.2 preprocedure vs 4.7 ± 0.6 postprocedure, P < .0001). The mean percent reductions in body weight, BMI, and HbA1c were 8.9% ± 1.2, 8.8% ± 1, and 21.4% ± 8.9, respectively. A statistically significant positive correlation was found between BMI and HbA1c after the procedure (r = 0.91, P = .0002). CONCLUSIONS: LGAE is well tolerated and leads to clinically significant decreases in weight and HbA1c in obese, prediabetic patients.
PURPOSE: To evaluate the effect of left gastric artery embolization (LGAE) on glycated hemoglobin (HbA1c) in a prospective obese, prediabetic cohort. MATERIALS AND METHODS: This prospective pilot study included 10 obese, prediabeticpatients (7 females and 3 males; mean age 37.5 ± 8.8 years; range 28-51 years) admitted to the Interventional Radiology Unit between January 2017 and June 2018 for LGAE for weight reduction. The main inclusion criteria were body mass index (BMI) >30 kg/m2 and HbA1c ranging from 5.7 to 6.4. Body weight, BMI, and HbA1c were assessed for each patient preprocedure and at 6 months postprocedure. Statistical analysis was performed using a paired sample t test. RESULTS: The baseline mean body weight, BMI, and HbA1c were 107.4 ± 12.8 kg, 37.4 ± 3.3 kg/m2, and 6 ± 0.2, respectively. Concerning complications, no serious adverse events were detected. Six months after the procedure, the mean body weight and BMI significantly decreased to 98 ± 11.6 kg and 34.1 ± 3 kg/m2, respectively (P < .0001). A paired sample t test showed a significant reduction in HbA1c from pre- to postprocedure (6.1 ± 0.2 preprocedure vs 4.7 ± 0.6 postprocedure, P < .0001). The mean percent reductions in body weight, BMI, and HbA1c were 8.9% ± 1.2, 8.8% ± 1, and 21.4% ± 8.9, respectively. A statistically significant positive correlation was found between BMI and HbA1c after the procedure (r = 0.91, P = .0002). CONCLUSIONS: LGAE is well tolerated and leads to clinically significant decreases in weight and HbA1c in obese, prediabeticpatients.
Authors: Jenanan Vairavamurthy; Frank Yuan; Robert A Anders; Dara L Kraitchman; Clifford R Weiss Journal: J Vasc Interv Radiol Date: 2022-01 Impact factor: 3.464
Authors: Clifford R Weiss; Yingli Fu; Cyrus Beh; Charles Hu; Dorota Kedziorek; Eun-Ji Shin; Robert A Anders; Aravind Arepally; Dara L Kraitchman Journal: J Vasc Interv Radiol Date: 2020-08-14 Impact factor: 3.464